The roots of Nardostachys jatamansi inhibits lipopolysaccharide-induced endotoxin shock.
Nardostachys jatamansi (NJ) has been used in the treatment of inflammatory diseases. However, it is not clear how NJ produces anti-inflammatory effects. In the present study, using an experimental model of lipopolysaccharide (LPS)-induced endotoxin shock, the protective effects and mechanisms of action of NJ were investigated. The water extract of roots of NJ was administrated to mice orally (1, 5, and 10 mg/kg) 1 h after or before LPS challenge. The administration of NJ inhibited LPS-induced endotoxin shock and the production of inflammatory mediators, such as interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-α/β. Murine peritoneal macrophages were used to determine the production of inflammatory mediators. In peritoneal macrophages, NJ also inhibited LPS-induced production of inflammatory mediators, such as IL-1β, IL-6, TNF-α, and IFN-α/β. In addition, NJ reduced the activation of mitogen-activated protein kinases (MAPKs) and the level of expression of interferon regulatory factor (IRF)-1 and IRF-7 mRNA. Furthermore, post-treatment with NJ reduced LPS-induced endotoxin shock and the production of inflammatory mediators. These results suggest that NJ inhibits endotoxin shock by inhibiting the production of IL-1β, IL-6, TNF-α, and IFN-α/β through the inhibition of MAPKs activation and IRF induction.
Bae
Gi-Sang
GS
Department of Herbology, School of Oriental Medicine, Wonkwang University, Iksan, Jeonbuk 540-749, South Korea.
Seo
Sang-Wan
SW
Kim
Min-Sun
MS
Park
Kyoung-Chel
KC
Koo
Bon Soon
BS
Jung
Won-Seok
WS
Cho
Gil-Hwan
GH
Oh
Hyun Cheol
HC
Yun
Seung-Won
SW
Kim
Jong-Jin
JJ
Kim
Sung Gyu
SG
Hwang
Sung-Yeon
SY
Song
Ho-Joon
HJ
Park
Sung-Joo
SJ
D000818:Animals; D015153:Blotting, Western; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D032404:Nardostachys / Q000737:chemistry*; D010936:Plant Extracts / Q000737:chemistry* / Q000627:therapeutic use*; D018517:Plant Roots / Q000737:chemistry*; D012772:Shock, Septic / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D053583:Interleukin-1beta; D015850:Interleukin-6; D008070:Lipopolysaccharides; D010936:Plant Extracts; D014409:Tumor Necrosis Factor-alpha
Pharmacol Biochem Behav. 2006 Jan;83(1):150-60
16500697
Cell. 1996 Feb 9;84(3):443-50
8608598
Cell Mol Immunol. 2005 Feb;2(1):20-7
16212907
Cell Mol Immunol. 2006 Feb;3(1):21-8
16549045
Res Immunol. 1992 Sep;143(7):759-63
1439152
Science. 1990 Sep 21;249(4975):1431-3
1698311
Pharmacol Ther. 1999 May-Jun;82(2-3):231-9
10454200
Pancreas. 2010 May;39(4):520-9
19940795
Nat Rev Immunol. 2003 Sep;3(9):745-56
12949498
Crit Care Clin. 2000 Apr;16(2):179-92
10768078
Science. 1986 Oct 24;234(4775):470-4
3764421
Nat Immunol. 2003 May;4(5):471-7
12679810
Clin Sci (Lond). 1998 Jun;94(6):557-72
9854452
Intensive Care Med. 2000;26 Suppl 1:S64-74
10786961
Planta Med. 1991 Feb;57(1):96-7
17226134
J Immunol. 1999 Apr 1;162(7):3749-52
10201887
Immunology. 2004 Oct;113(2):153-62
15379975
Nat Rev Immunol. 2003 Feb;3(2):169-76
12563300
Chest. 2000 Aug;118(2):503-8
10936147
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2774-8
8610116
Annu Rev Med. 1994;45:491-503
8198398
Immunopharmacology. 1990 Mar-Apr;19(2):93-101
1693607
Nat Immunol. 2002 Apr;3(4):392-8
11896392
Oncogene. 1992 Apr;7(4):703-10
1373483
J Clin Invest. 2008 May;118(5):1680-90
18382764
J Exp Med. 2003 Oct 6;198(7):1043-55
14517278
Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62
12209125
Drugs. 1996;52 Suppl 2:9-17
8869831
Spec Rep Ser Indian Counc Med Res. 1965;51:1-117
5844450
J Immunol. 1998 Dec 15;161(12):6947-54
9862729